BioAge Labs (NASDAQ:BIOA) Reaches New 52-Week High – Here’s What Happened

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $16.18 and last traded at $15.41, with a volume of 2006551 shares trading hands. The stock had previously closed at $12.62.

Analysts Set New Price Targets

A number of research firms have recently weighed in on BIOA. Wall Street Zen upgraded BioAge Labs from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Finally, Citigroup increased their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $15.00.

BioAge Labs Trading Up 22.1%

The firm’s 50-day moving average is $10.35. The firm has a market capitalization of $552.45 million, a P/E ratio of -10.14 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The company had revenue of $2.05 million for the quarter.

Insiders Place Their Bets

In related news, insider Paul D. Rubin sold 18,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total transaction of $216,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BIOA. JPMorgan Chase & Co. raised its position in shares of BioAge Labs by 228.7% in the third quarter. JPMorgan Chase & Co. now owns 36,848 shares of the company’s stock worth $217,000 after buying an additional 25,638 shares in the last quarter. Millennium Management LLC boosted its position in shares of BioAge Labs by 749.8% during the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after acquiring an additional 270,479 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after purchasing an additional 3,517 shares in the last quarter. Occudo Quantitative Strategies LP bought a new position in shares of BioAge Labs in the third quarter worth approximately $113,000. Finally, Two Sigma Investments LP raised its stake in BioAge Labs by 54.3% in the third quarter. Two Sigma Investments LP now owns 99,669 shares of the company’s stock valued at $586,000 after purchasing an additional 35,068 shares in the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.